Ascendis Pharma A/S - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ASND Nasdaq 2836 ascendispharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ascendis Pharma A/S

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference - Jan 12th, 2025 10:00 pm
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Jan 6th, 2025 1:30 pm
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains? - Dec 23rd, 2024 1:46 pm
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults - Dec 19th, 2024 1:30 pm
Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk - Dec 18th, 2024 11:28 am
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26 - Dec 16th, 2024 1:30 pm
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency - Dec 12th, 2024 9:01 pm
Exploring Three High Growth Tech Stocks in the United States - Dec 12th, 2024 2:06 pm
Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia - Dec 11th, 2024 4:09 pm
Ascendis Pharma Reports Third Quarter 2024 Financial Results - Nov 14th, 2024 9:01 pm
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 - Nov 7th, 2024 9:01 pm
High Growth Tech Stocks In The United States To Watch - Nov 6th, 2024 6:02 pm
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA - Nov 5th, 2024 5:12 pm
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology - Nov 5th, 2024 3:00 pm
Ascendis Pharma and Novo Nordisk Join Forces - Nov 5th, 2024 12:27 pm
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform - Nov 5th, 2024 12:10 pm
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug - Nov 4th, 2024 6:34 pm
Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases - Nov 4th, 2024 4:01 pm
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases - Nov 4th, 2024 12:00 pm
Ascendis Pharma submits sBLA for growth hormone deficiency therapy - Oct 1st, 2024 2:13 pm